Dexcom Inc
NASDAQ:DXCM

  • LAST PRICE
    115.7900
  • TODAY'S CHANGE (%)
    0.4900 (0.4250%)
  • Bid / Lots
    114.5000/ 3
  • Ask / Lots
    117.0200/ 3
  • Open / Previous Close
    114.7300 / 115.3000
  • Day Range
    114.2416
    116.5800
  • 52 Week Range
    74.7500
    142.0000
  • Volume
    2,967,330

Search Criteria

Click on magnifying glass icon to search

CompanyCountrySymbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

  • Jun 5, 2024

      Show headlines and story abstract

    • 6:00AM ET on Wednesday Jun 05, 2024 by Business Wire
      Companies Mentioned: DXCM

      DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the Dexcom G7 Continuous Glucose Monitoring (CGM) System now connects directly to Apple Watch* in the United States. Dexcom G7 is the first and only CGM available with Direct to Apple Watch, offering users the freedom and convenience of real-time glucose readings on their wrist even when their iPhone isn't with them.+

    • 6:00AM ET on Wednesday Jun 05, 2024 by Dow Jones
      Companies Mentioned: DXCM
      -- Diabetes management goes hands-free as Dexcom G7 now connects directly to Apple Watch* in the U.S., giving users confidence even when their iPhone isn't with them -- As the first and only CGM system that connects directly to Apple Watch,* Dexcom G7 gives users the freedom and convenience of real-time glucose readings on their wrist -- Direct to Apple Watch is now available to Dexcom G7 users in the United States, United Kingdom and Ireland, with additional markets launching later this month SAN DIEGO--(BUSINESS WIRE)--June 05, 2024--

  • Jun 4, 2024

      Show headlines and story abstract

    • 10:16AM ET on Tuesday Jun 04, 2024 by Dow Jones
      Companies Mentioned: DXCM
      EDINBURGH, Scotland--(BUSINESS WIRE)--June 04, 2024--
      DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company, which pioneered CGM technology 25 years ago, has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c >= 8%) access to Dexcom's life-changing technology. The French government is the first in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the USA and New Zealand.

    • 7:00AM ET on Tuesday Jun 04, 2024 by Business Wire
      Companies Mentioned: DXCM

      DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, today announced a significant advancement in access to its products for those treating Type 2 diabetes (T2D) with basal insulin injections. The company, which pioneered CGM technology 25 years ago, has secured access to its Dexcom ONE sensor for around 100,000 T2D users in France. The reimbursement guidance offers people aged over two years who are on non-intensified insulin therapy (less than 3 injections a day) and whose glycaemic control is insufficient (HbA1c greater-than or equal to 8%) access to Dexcom's life-changing technology. The French government is the first in Europe to offer full national reimbursement for Dexcom CGM technology to those treating T2D with basal injections, following other countries around the world such as the USA and New Zealand.

  • Jun 3, 2024

Peers Headlines